Gilead Sciences Inc (GILD)

$121.26 -2.81 (-2.26%)
Market Cap 153.93B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
EPS (ttm) N/A
PE Ratio 14.87
Forward PE 14.28
Profit Margin 1.67%
Debt to Equity Ratio 1.16
Volume 6,659,700
Avg Vol 6,798,024
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 53%
Beta 0.33
Analysts Strong Sell
Price Target $135.48

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 578 9264
Address:
333 Lakeside Drive, Foster City, United States
Reanimated666
Reanimated666 Jan. 15 at 1:42 PM
$GILD Wow not down 3 you POS. Are we finally going to breakout?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 15 at 2:47 AM
Enter: $GILD Calls Strike Price: $122 Expiry Date: FEB 06 2026 Buy in Price: $3.62 - $3.75 Sell Price: $5.61 Profit : +55% (Turn every $1 into $1.55) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Pearl_Power
Pearl_Power Jan. 14 at 9:38 PM
$GILD love this
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:06 AM
$SNDL Just one of TONS OF STUDIES ON BENEFITS= "Nanoparticle Delivery of CBD Shows Strong Tumor Inhibition in Triple-Negative Breast Cancer By Anthony Martinelli in News, Studies A study published today by Oxford Academic’s Journal of Pharmacy and Pharmacology finds that cannabidiol (CBD), when delivered through a folic acid-modified chitosan (FA-CS) nanoparticle system, significantly inhibited tumor growth in triple-negative breast cancer (TNBC), an aggressive form of the disease with few effective treatment options." Aug 2025 https://themarijuanaherald.com/2025/08/nanoparticle-delivery-of-cbd-shows-strong-tumor-inhibition-in-triple-negative-breast-cancer/ $TLRY $IBB $GILD $CURLF
0 · Reply
wheresdannynow
wheresdannynow Jan. 13 at 9:09 PM
The whole biotech space rose 33.5% in 2025 per IBD, with standouts like $GILD and $ALNY posting big wins
1 · Reply
Davidendz
Davidendz Jan. 13 at 9:01 PM
Biotech sector crushed 2025 with IBD group up 33.5% Big names like $AMGN +25.6%, $GILD +32.9%, and $ALNY +69% leading the charge. This tailwind into 2026 is perfect for DPX platform plays like $BIOV.CSE $BVAXF fresh off strong Jan 8 NMIBC Phase 1 T-cell data.
0 · Reply
Hero07
Hero07 Jan. 13 at 7:15 PM
$NUVB Dr. Hung knows the Value in stacking ROA1 patients, and Drug and drug conjugation platform. this will be the next $CDTX buyout, $GILD looking yet!
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 13 at 4:41 PM
$GILD Current Stock Price: $122.67 Contracts to trade: $125 GILD Jan 16 2026 Call Entry: $0.57 Exit: $1.04 ROI: 82% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 13 at 4:13 PM
Enter: $GILD Calls Strike Price: $121 Expiry Date: FEB 06 2026 Buy in Price: $4.20 - $4.45 Sell Price: $7.56 Profit : +80% (Turn every $1 into $1.80) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Noobnr1
Noobnr1 Jan. 13 at 5:39 AM
$NYXH 🚀 netto gain increases with 348% 👏 $PHAR $BEAM $OMER $GILD 💎
0 · Reply
Latest News on GILD
Gilead Sciences: From All-Time Highs To Higher Highs

Jan 12, 2026, 5:40 PM EST - 3 days ago

Gilead Sciences: From All-Time Highs To Higher Highs

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

Jan 12, 2026, 3:58 PM EST - 3 days ago

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

CVS

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:46 PM EST - 3 days ago

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Jan 12, 2026, 9:21 AM EST - 3 days ago

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Jan 6, 2026, 7:00 AM EST - 9 days ago

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Gilead Sciences to Present at Upcoming Investor Conference

Dec 22, 2025, 4:05 PM EST - 24 days ago

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

Dec 22, 2025, 8:00 AM EST - 24 days ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

ASMB

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 27 days ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 27 days ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GSK MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 27 days ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GSK MRK NVS SNY

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Dec 19, 2025, 2:21 PM EST - 27 days ago

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 27 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY LLY MRK NVO

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Dec 18, 2025, 8:30 AM EST - 4 weeks ago

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Gilead's experimental HIV treatment meets main goal in late-stage trial

Dec 15, 2025, 8:43 AM EST - 4 weeks ago

Gilead's experimental HIV treatment meets main goal in late-stage trial

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Dec 15, 2025, 8:30 AM EST - 4 weeks ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Gilead, Arcus scrap late-stage trial of cancer drug combo

Dec 12, 2025, 8:36 AM EST - 4 weeks ago

Gilead, Arcus scrap late-stage trial of cancer drug combo

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Dec 9, 2025, 8:30 AM EST - 5 weeks ago

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Dec 7, 2025, 8:00 AM EST - 5 weeks ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

Dec 6, 2025, 2:00 PM EST - 5 weeks ago

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Dec 6, 2025, 2:00 PM EST - 5 weeks ago

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:13 PM EST - 6 weeks ago

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 1:23 AM EST - 6 weeks ago

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Gilead Sciences: About To Break Out

Nov 25, 2025, 6:17 AM EST - 7 weeks ago

Gilead Sciences: About To Break Out

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Nov 24, 2025, 8:30 AM EST - 7 weeks ago

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Nov 20, 2025, 4:46 PM EST - 2 months ago

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 2 months ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY IVV MRK PFE SPY VOO

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Nov 20, 2025, 7:02 AM EST - 2 months ago

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 11:23 AM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GSK JNJ LLY

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Nov 18, 2025, 5:00 AM EST - 2 months ago

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Nov 13, 2025, 1:55 PM EST - 2 months ago

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Can Gilead Stock Outrun Regeneron In The Next Rally?

Nov 13, 2025, 9:00 AM EST - 2 months ago

Can Gilead Stock Outrun Regeneron In The Next Rally?

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Nov 13, 2025, 8:30 AM EST - 2 months ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 2:41 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Nov 10, 2025, 4:00 AM EST - 2 months ago

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Gilead's breast cancer drug fails to meet main goal of late-stage study

Nov 7, 2025, 8:41 AM EST - 2 months ago

Gilead's breast cancer drug fails to meet main goal of late-stage study

Gilead Provides Update on Phase 3 ASCENT-07 Study

Nov 7, 2025, 8:30 AM EST - 2 months ago

Gilead Provides Update on Phase 3 ASCENT-07 Study

Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

Nov 7, 2025, 8:00 AM EST - 2 months ago

Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

Gilead Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 4:05 PM EST - 2 months ago

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Nov 3, 2025, 9:10 AM EST - 2 months ago

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Oct 31, 2025, 1:41 PM EDT - 2 months ago

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Oct 31, 2025, 8:00 AM EDT - 2 months ago

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 8:56 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Oct 30, 2025, 4:05 PM EDT - 2 months ago

Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Gilead Sciences Announces Third Quarter 2025 Financial Results

Oct 30, 2025, 4:02 PM EDT - 2 months ago

Gilead Sciences Announces Third Quarter 2025 Financial Results

Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes

Oct 29, 2025, 4:11 PM EDT - 2 months ago

Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Oct 28, 2025, 10:40 AM EDT - 2 months ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

ABBV LLY MRK

What To Expect From Gilead In Q3 2025

Oct 24, 2025, 10:56 AM EDT - 2 months ago

What To Expect From Gilead In Q3 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Oct 23, 2025, 8:00 AM EDT - 3 months ago

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Final Trade: F, HAL, MA, GILD

Oct 21, 2025, 6:21 PM EDT - 3 months ago

Final Trade: F, HAL, MA, GILD

F HAL MA

Reanimated666
Reanimated666 Jan. 15 at 1:42 PM
$GILD Wow not down 3 you POS. Are we finally going to breakout?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 15 at 2:47 AM
Enter: $GILD Calls Strike Price: $122 Expiry Date: FEB 06 2026 Buy in Price: $3.62 - $3.75 Sell Price: $5.61 Profit : +55% (Turn every $1 into $1.55) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Pearl_Power
Pearl_Power Jan. 14 at 9:38 PM
$GILD love this
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:06 AM
$SNDL Just one of TONS OF STUDIES ON BENEFITS= "Nanoparticle Delivery of CBD Shows Strong Tumor Inhibition in Triple-Negative Breast Cancer By Anthony Martinelli in News, Studies A study published today by Oxford Academic’s Journal of Pharmacy and Pharmacology finds that cannabidiol (CBD), when delivered through a folic acid-modified chitosan (FA-CS) nanoparticle system, significantly inhibited tumor growth in triple-negative breast cancer (TNBC), an aggressive form of the disease with few effective treatment options." Aug 2025 https://themarijuanaherald.com/2025/08/nanoparticle-delivery-of-cbd-shows-strong-tumor-inhibition-in-triple-negative-breast-cancer/ $TLRY $IBB $GILD $CURLF
0 · Reply
wheresdannynow
wheresdannynow Jan. 13 at 9:09 PM
The whole biotech space rose 33.5% in 2025 per IBD, with standouts like $GILD and $ALNY posting big wins
1 · Reply
Davidendz
Davidendz Jan. 13 at 9:01 PM
Biotech sector crushed 2025 with IBD group up 33.5% Big names like $AMGN +25.6%, $GILD +32.9%, and $ALNY +69% leading the charge. This tailwind into 2026 is perfect for DPX platform plays like $BIOV.CSE $BVAXF fresh off strong Jan 8 NMIBC Phase 1 T-cell data.
0 · Reply
Hero07
Hero07 Jan. 13 at 7:15 PM
$NUVB Dr. Hung knows the Value in stacking ROA1 patients, and Drug and drug conjugation platform. this will be the next $CDTX buyout, $GILD looking yet!
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 13 at 4:41 PM
$GILD Current Stock Price: $122.67 Contracts to trade: $125 GILD Jan 16 2026 Call Entry: $0.57 Exit: $1.04 ROI: 82% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 13 at 4:13 PM
Enter: $GILD Calls Strike Price: $121 Expiry Date: FEB 06 2026 Buy in Price: $4.20 - $4.45 Sell Price: $7.56 Profit : +80% (Turn every $1 into $1.80) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Noobnr1
Noobnr1 Jan. 13 at 5:39 AM
$NYXH 🚀 netto gain increases with 348% 👏 $PHAR $BEAM $OMER $GILD 💎
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 13 at 2:24 AM
$GILD Share Price: $122.59 Contract Selected: Feb 06, 2026 $125 Calls Buy Zone: $1.95 – $2.42 Target Zone: $3.58 – $4.38 Potential Upside: 73% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 12:45 AM
$SLS $GILD paid $4.9B for $FTSV based on PH1 Trial Data for AML-MR patients - that wasn't as good as the SLS009 Phase 2 Data Published at ASH. - just the SLS secondary Asset has a comp of $4.9B right now - implies a ROI of 600%. https://www.reddit.com/r/sellasLifescience/comments/1m7p1og/magrolimab_was_bought_for_49b_based_on_lesser/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
1 · Reply
RunnerSignals
RunnerSignals Jan. 12 at 9:05 PM
$DDOG $GILD $HD $NFLX $NOW Analysts see growth everywhere. Are you watching or just scrolling https://stocksrunner.com/news/2026-01-12-stock-upgrades-today
0 · Reply
Dorps332
Dorps332 Jan. 12 at 4:33 PM
$GILD what’s up with the $135 calls bought today for this week?
0 · Reply
JuneMoscowitz260
JuneMoscowitz260 Jan. 12 at 4:18 PM
$GILD $ERAS Biotech depth shown
0 · Reply
Noobnr1
Noobnr1 Jan. 12 at 3:08 PM
$BEAM 🚀🚀$PHAR 💎🐇 $GILD $OMER $PFE 🍀🤞
0 · Reply
Buy_SoFi
Buy_SoFi Jan. 12 at 2:48 PM
$TLTFF $IBRX $GILD $PFE $MRK https://stockhouse.com/companies/bullboard?symbol=v.tlt
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 12 at 9:00 AM
$GILD trading at $121 with below-average volume, while $VRTX sitting at $464 with above-average volume. $VRTX showing more strength with a higher price compared to $GILD. Both in the Healthcare sector - any upcoming catalysts to watch for in this space?
0 · Reply
redenergy
redenergy Jan. 11 at 9:12 PM
$GILD https://trialradar.com/c/gilead-sciences/en-us/default/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 11 at 8:28 PM
Enter: $GILD Calls Strike Price: $122 Expiry Date: FEB 06 2026 Buy in Price: $3.87 - $3.95 Sell Price: $5.96 Profit : +54% (Turn every $1 into $1.54) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
doctordinero
doctordinero Jan. 9 at 8:57 PM
Added March OTM calls $GILD $PEP $QCOM GLTA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 9 at 8:18 PM
Enter: $GILD Calls Strike Price: $124 Expiry Date: JAN 30 2026 Buy in Price: $2.35 - $2.47 Sell Price: $5.22 Profit : +122% (Turn every $1 into $2.22) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply